Surmodics (NASDAQ:SRDX) Issues FY 2025 Earnings Guidance

Surmodics (NASDAQ:SRDX - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of -0.620--0.420 for the period, compared to the consensus earnings per share estimate of -0.260. The company issued revenue guidance of $114.0 million-$117.0 million, compared to the consensus revenue estimate of $127.3 million.

Analysts Set New Price Targets

Several equities research analysts have issued reports on SRDX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a research note on Wednesday, April 30th. StockNews.com initiated coverage on Surmodics in a report on Monday, February 3rd. They issued a "hold" rating for the company. Finally, Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price objective on the stock in a research note on Friday, March 7th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $43.00.

Surmodics Stock Performance

SRDX stock traded down $0.60 during trading on Monday, hitting $27.04. 26,143 shares of the company's stock traded hands, compared to its average volume of 277,211. Surmodics has a 52 week low of $26.00 and a 52 week high of $42.44. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26. The stock has a fifty day moving average price of $29.43 and a two-hundred day moving average price of $34.86. The stock has a market capitalization of $386.64 million, a price-to-earnings ratio of -26.77 and a beta of 1.32.

Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). The business had revenue of $28.09 million for the quarter, compared to analyst estimates of $32.23 million. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. As a group, equities analysts anticipate that Surmodics will post 0.2 EPS for the current fiscal year.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).